# EDGAR Filing Document

**Accession Number:** 0001710072
**File Stem:** 0001104659-26-057287
**Filing Date:** 2026-5
**Character Count:** 35109
**Document Hash:** fc0ec812ba8bbb9a8ca1f42ad561dc7d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-057287.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001104659-26-057287

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**EFFECTIVENESS DATE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Edgewise Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001710072
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 821725586
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295663
- **FILM NUMBER:** 26954895

**BUSINESS ADDRESS:**
- **STREET 1:** 1715 38TH ST
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301
- **BUSINESS PHONE:** 720-262-7002

**MAIL ADDRESS:**
- **STREET 1:** 1715 38TH ST
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301

**As filed with the Securities and Exchange Commission on May 7, 2026**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***Under***

***The Securities Act of 1933***

**EDGEWISE THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **82-1725586** |
|  **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**1715 38<sup>th</sup> Street**

**Boulder, CO 80301**

**(Address of Principal Executive Offices) (Zip Code)**

**2021 Equity Incentive Plan**

**2021 Employee Stock Purchase Plan**

**(Full title of the plan)**

**Kevin Koch, Ph.D.**

**President and Chief Executive Officer**

**Edgewise Therapeutics, Inc.**

**1715 38<sup>th</sup> Street**

**Boulder, CO 80301**

**(Name and address of agent for service)**

**(720) 262-7002**

**(Telephone number, including area code, of agent for service)**

***Copies to:***

---

| | |
|:---|:---|
| **Kenneth A. Clark**<br> **Tony Jeffries**<br> **Jennifer Knapp**<br> **Wilson Sonsini Goodrich & Rosati**<br> **Professional Corporation**<br> **1155 Canyon Blvd., Suite 400**<br> **Boulder, CO 80302-5195**<br> **(303) 256-5900** | **Michael Nofi**<br> **Chief Financial Officer**<br> **Edgewise Therapeutics, Inc.**<br> **1715 38<sup>th</sup> Street**<br> **Boulder, CO 80301**<br> **(720) 262-7002** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ⌧ | Accelerated filer | ◻ |
| Non-accelerated filer | ◻ | Smaller reporting company | ◻ |
|  |  | Emerging growth company | ◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (this "Registration Statement") in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the "Securities Act") and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.** **Incorporation of Documents by Reference.**

Edgewise Therapeutics, Inc. (the "Registrant") hereby incorporates by reference into this Registration Statement the following documents previously filed with the Securities and Exchange Commission (the "Commission"):

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Registrant's [Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on February 26, 2026](https://www.sec.gov/Archives/edgar/data/1710072/000110465926020112/ewtx-20251231x10k.htm) ;

&nbsp;&nbsp;&nbsp;&nbsp;(2) The information incorporated by reference into the Registrant's Annual Report on Form 10-K for the year ended December 31,
2025 from its [Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 23, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001710072/000110465926047688/ewtx-20260604xdef14a.htm) ;

&nbsp;&nbsp;&nbsp;&nbsp;(3) The Registrant's [Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, filed with the Commission on May 7, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/1710072/000110465926056713/ewtx-20260331x10q.htm) ;

&nbsp;&nbsp;&nbsp;&nbsp;(4) All other reports filed with the Commission pursuant to Sections 13(a) or 15(d) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act") since the end of the fiscal year covered by the Registrant's Annual Report referred
to in (1) above; and

&nbsp;&nbsp;&nbsp;&nbsp;(5) The description of the Registrant's Common Stock contained
 in the Company's Registration Statement on [Form 8-A (File No. 001-40236) filed with the Commission on March 17, 2021](https://www.sec.gov/Archives/edgar/data/1710072/000110465921037695/tm2037601d12_8a12b.htm) , including any amendment or report filed
 for the purpose of updating such description.

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; *provided*, *however*, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 4.** **Description of Securities.**

Not applicable.

**Item 5.** **Interests of Named Experts and Counsel.**

Not applicable.

**Item 6.** **Indemnification of Directors and Officers.**

Section 145 of the Delaware General Corporation Law empowers a corporation to indemnify its directors and officers and to purchase insurance with respect to liability arising out of their capacity or status as directors and officers, provided that the person acted in good faith and in a manner the person reasonably believed to be in the corporation's best interests, and, with respect to any criminal action, had no reasonable cause to believe the person's actions were unlawful. The Delaware General Corporation Law further provides that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be entitled under the corporation's bylaws, any agreement, a vote of stockholders or otherwise. The Amended and Restated Certificate of Incorporation of the Registrant provides for the indemnification of the Registrant's directors to the fullest extent permitted under the Delaware General Corporation Law. In addition, the Amended and Restated Bylaws of the Registrant require the Registrant to fully indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (whether civil, criminal, administrative or investigative) by reason of the fact that such person is or was a director or officer of the Registrant, or is or was a director or officer of the Registrant serving at the Registrant's request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney's fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, to the fullest extent permitted by applicable law.

Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director or officer of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except (1) for any breach of the director's or officer's duty of loyalty to the corporation or its stockholders, (2) for acts or omissions by a director or officer not in good faith or which involve intentional misconduct or a knowing violation of law, (3) with respect to a director, for payments of unlawful dividends or unlawful stock repurchases or redemptions, (4) for any transaction from which the director or officer derived an improper personal benefit or (5) for claims against an officer in any action by or in the right of the corporation. The officers who may be exculpated pursuant to Section 102(b)(7) of the Delaware General Corporation Law are only officers who at the time of an act or omission as to which liability is asserted are deemed to have consented to service of process to the registered agent of the corporation under Delaware law. The Amended and Restated Certificate of Incorporation of the Registrant provides that the Registrant's directors and officers shall not be personally liable to it or its stockholders for monetary damages for breach of fiduciary duty as a director or officer to the fullest extent permitted by the Delaware General Corporation Law and that if the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of the Registrant's directors and officers shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended.

Section 174 of the Delaware General Corporation Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either absent when the unlawful actions were approved, or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.

As permitted by the Delaware General Corporation Law, the Registrant has entered into separate indemnification agreements with each of the Registrant's directors and certain of the Registrant's officers which require the Registrant, among other things, to indemnify them against certain liabilities which may arise by reason of their status as directors, officers or certain other employees.

The Registrant expects to obtain and maintain insurance policies under which its directors and officers are insured, within the limits and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits or proceedings to which they are parties by reason of being or having been directors or officers. The coverage provided by these policies may apply whether or not the Registrant would have the power to indemnify such person against such liability under the provisions of the Delaware General Corporation Law.

These indemnification provisions and the indemnification agreements entered into between the Registrant and the Registrant's officers and directors may be sufficiently broad to permit indemnification of the Registrant's officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act of 1933, as amended.

**Item 7.** **Exemption from Registration Claimed.**

Not applicable.

**Item 8.** **Exhibits.**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| <br>**Exhibit<br> Number** | <br>**Description** | **Form** | **File No.** | **Exhibit** | **Filing Date** |
| [4.2](https://www.sec.gov/Archives/edgar/data/1710072/000110465921039429/tm2037601d10_ex4-2.htm) | [Specimen common stock certificate of the Registrant](https://www.sec.gov/Archives/edgar/data/1710072/000110465921039429/tm2037601d10_ex4-2.htm) | [S-1/A](https://www.sec.gov/Archives/edgar/data/1710072/000110465921039429/tm2037601d10_ex4-2.htm) | [333-253923](https://www.sec.gov/Archives/edgar/data/1710072/000110465921039429/tm2037601d10_ex4-2.htm) | [4.2](https://www.sec.gov/Archives/edgar/data/1710072/000110465921039429/tm2037601d10_ex4-2.htm) | [3/22/2021](https://www.sec.gov/Archives/edgar/data/1710072/000110465921039429/tm2037601d10_ex4-2.htm) |
| [5.1\*](tm2613274d1_ex5-1.htm) | [Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation](tm2613274d1_ex5-1.htm) |  |  |  |  |
| [10.1](https://www.sec.gov/Archives/edgar/data/1710072/000110465921039429/tm2037601d10_ex10-3.htm) | [2021 Equity Incentive Plan and forms of agreements thereunder](https://www.sec.gov/Archives/edgar/data/1710072/000110465921039429/tm2037601d10_ex10-3.htm) | [S-1/A](https://www.sec.gov/Archives/edgar/data/1710072/000110465921039429/tm2037601d10_ex10-3.htm) | [333-253923](https://www.sec.gov/Archives/edgar/data/1710072/000110465921039429/tm2037601d10_ex10-3.htm) | [10.3](https://www.sec.gov/Archives/edgar/data/1710072/000110465921039429/tm2037601d10_ex10-3.htm) | [3/22/2021](https://www.sec.gov/Archives/edgar/data/1710072/000110465921039429/tm2037601d10_ex10-3.htm) |
| [10.2](http://www.sec.gov/Archives/edgar/data/1710072/000155837023009268/ewtx-20230331xex10d2.htm) | [Form of Restricted Stock Unit Agreement](http://www.sec.gov/Archives/edgar/data/1710072/000155837023009268/ewtx-20230331xex10d2.htm) | [10-Q](http://www.sec.gov/Archives/edgar/data/1710072/000155837023009268/ewtx-20230331xex10d2.htm) | [001-40236](http://www.sec.gov/Archives/edgar/data/1710072/000155837023009268/ewtx-20230331xex10d2.htm) | [10.2](http://www.sec.gov/Archives/edgar/data/1710072/000155837023009268/ewtx-20230331xex10d2.htm) | [5/11/2023](http://www.sec.gov/Archives/edgar/data/1710072/000155837023009268/ewtx-20230331xex10d2.htm) |
| [10.3](https://www.sec.gov/Archives/edgar/data/1710072/000155837023001895/ewtx-20221231xex10d5.htm) | [2021 Employee Stock Purchase Plan, as amended, and forms of agreements thereunder](https://www.sec.gov/Archives/edgar/data/1710072/000155837023001895/ewtx-20221231xex10d5.htm) | [10-K](https://www.sec.gov/Archives/edgar/data/1710072/000155837023001895/ewtx-20221231xex10d5.htm) | [001-40236](https://www.sec.gov/Archives/edgar/data/1710072/000155837023001895/ewtx-20221231xex10d5.htm) | [10.5](https://www.sec.gov/Archives/edgar/data/1710072/000155837023001895/ewtx-20221231xex10d5.htm) | [2/23/2023](https://www.sec.gov/Archives/edgar/data/1710072/000155837023001895/ewtx-20221231xex10d5.htm) |
| [23.1\*](tm2613274d1_ex23-1.htm) | [Consent of Independent Registered Public Accounting Firm](tm2613274d1_ex23-1.htm) |  |  |  |  |
| [23.2\*](tm2613274d1_ex5-1.htm) | [Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)](tm2613274d1_ex5-1.htm) |  |  |  |  |
| [24.1\*](#a_002) | [Power of Attorney (contained on signature page hereto)](#a_002) |  |  |  |  |
| [107\*](tm2613274d1_ex-filingfees.htm) | [Filing Fee Table](tm2613274d1_ex-filingfees.htm) |  |  |  |  |

---

------

\*Filed herewith.

---

| | |
|:---|:---|
| **Item 9** | **Undertakings.** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Filing Fee Tables" or "Calculation of Registration Fee" table, as applicable, in the effective Registration Statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

*provided*, *however*, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boulder, Colorado, on May 7, 2026.

---

| | |
|:---|:---|
| **EDGEWISE THERAPEUTICS, INC.** | **EDGEWISE THERAPEUTICS, INC.** |
| By: | /s/ Kevin Koch |
|  | Kevin Koch, Ph.D. |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin Koch, Ph.D., Michael Nofi and John R. Moore as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement and any and all amendments thereto (including post-effective amendments), and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully for all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Kevin Koch | President, Chief Executive Officer and Director *(Principal Executive Officer)* | May 7, 2026 |
| Kevin Koch, Ph.D. | President, Chief Executive Officer and Director *(Principal Executive Officer)* |  |
|  | Chief Financial Officer *(Principal Financial and Accounting Officer)* |  |
| /s/ Michael Nofi | Chief Financial Officer *(Principal Financial and Accounting Officer)* | May 7, 2026 |
| Michael Nofi |  |  |
| /s/ Peter Thompson | Co-Founder, Chairman and Director | May 7, 2026 |
| Peter Thompson, M.D. | Co-Founder, Chairman and Director |  |
| /s/ Alan Russell | Chief Scientific Officer and Director | May 7, 2026 |
| Alan Russell, Ph.D. | Chief Scientific Officer and Director |  |
| /s/ Laura A. Brege | Director | May 7, 2026 |
| Laura A. Brege | Director |  |
| /s/ Badreddin Edris | Co-Founder and Director | May 7, 2026 |
| Badreddin Edris, Ph.D. | Co-Founder and Director |  |
| /s/ Jonathan Fox | Director | May 7, 2026 |
| Jonathan Fox, M.D., Ph.D., FACC | Director |  |
| /s/ Christopher Martin | Director | May 7, 2026 |
| Christopher Martin | Director |  |
| /s/ Arlene Morris | Director | May 7, 2026 |
| Arlene Morris | Director |  |
| /s/ Jonathan Root | Director | May 7, 2026 |
| Jonathan Root, M.D. | Director |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](tm2613274d1_ex5-1img001.jpg) | Wilson Sonsini Goodrich & Rosati<br> Professional Corporation<br>1155 Canyon Blvd., Suite 400<br> Boulder, Colorado 80302-5195<br>o: 303.256.5900<br> f: 866.974.7329 |

---

May 7, 2026

Edgewise Therapeutics, Inc.

1715 38<sup>th</sup> St.

Boulder, CO 80301

---

| | |
|:---|:---|
| **Re:** | **Registration Statement on Form S-8** |

---

Ladies and Gentlemen:

At your request, we have examined the Registration Statement on Form S-8 (the "**Registration Statement**") to be filed by Edgewise Therapeutics, Inc., a Delaware corporation (the "**Company**"), with the Securities and Exchange Commission (the "**Commission**") on or about the date hereof, relating to the registration under the Securities Act of 1933, as amended (the "**Act**"), of shares of your common stock, par value $0.0001 per share (the "**Shares**"), consisting of: (i) 5,040,000 shares of common stock to be issued under the 2021 Equity Incentive Plan (the "**2021 Plan**"); and (ii) 1,008,000 shares of common stock to be issued under the 2021 Employee Stock Purchase Plan (the "**2021 ESPP**" and, together with the 2021 Plan, the "**Plans**"). As your legal counsel, we have reviewed the actions proposed to be taken by you in connection with the issuance and sale of the Shares to be issued under the Plans.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when issued and sold in the manner described in the Plans and pursuant to the agreements that accompany the Plans, will be legally and validly issued, fully paid, and nonassessable.

We hereby consent to the filing of this opinion as an exhibit to the above referenced Registration Statement and to the use of our name wherever it appears in the Registration Statement and in any amendments thereto. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Wilson Sonsini Goodrich & Rosati, P.C. |
| WILSON SONSINI GOODRICH & ROSATI <br> Professional Corporation |

---

austin boston BOULDER brussels CENTURY CITY hong kong london los angeles new york palo alto<br> SALT LAKE CITY san diego san francisco seattle shanghai washington, dc wilmington, de

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the use of our report dated February 26, 2026, with respect to the financial statements of Edgewise Therapeutics, Inc., and the effectiveness of internal control over financial reporting, incorporated herein by reference.

/s/ KPMG LLP

Denver, Colorado<br> May 7, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Edgewise Therapeutics, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, par value $0.0001 per share, reserved for issuance pursuant to the 2021 Employee Stock Purchase Plan | Other | 1008000 | $26.01 | $26218080.00 | 0.0001381 | $3620.72 |
| 2 | Equity | Common Stock, par value $0.0001 per share, reserved for issuance pursuant to the 2021 Equity Incentive Plan | Other | 5040000 | $30.59 | $154173600.00 | 0.0001381 | $21291.37 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $180391680.00  |  | $24912.09  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $24912.09  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement on Form S-8 ("Registration Statement") shall also cover any additional shares of the Registrant's common stock, $0.0001 par value per share ("Common Stock"), that become issuable under the Registrant's 2021 Employee Stock Purchase Plan (the "ESPP") by reason of an event such as any stock split, stock dividend or similar adjustment effected without the Registrant's receipt of consideration that increases the number of the Registrant's outstanding shares of Common Stock. Reflects an automatic annual increase of 1,008,000 on January 1, 2026 to the number of shares of Registrant's Common Stock reserved for issuance under the ESPP, which annual increase is provided for in the ESPP. Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of 85% of $30.59 per share, which represents the average of the high and low price per share of the Registrant's Common Stock on April 30, 2026, as reported on the Nasdaq Global Select Market, which date is within five business days prior to the filing of this Registration Statement. Pursuant to the ESPP, the purchase price of the shares of the Registrant's Common Stock reserved for issuance thereunder will be at least 85% of the lower of the fair market value on (i) the first trading day of the offering period or (ii) the purchase date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> Pursuant to Rule 416(a) under the Securities Act, this Registration Statement shall also cover any additional shares of the Registrant's Common Stock that become issuable under the Registrant's 2021 Equity Incentive Plan (the "2021 Plan") by reason of an event such as any stock split, stock dividend or similar adjustment effected without the Registrant's receipt of consideration that increases the number of the Registrant's outstanding shares of Common Stock. Reflects an automatic annual increase of 5,040,000 on January 1, 2026 to the number of shares of Registrant's Common Stock reserved for issuance under the 2021 Plan, which annual increase is provided for in the 2021 Plan. Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of $30.59 per share, which represents the average of the high and low prices of the Registrant's Common Stock on April 30, 2026, as reported on the Nasdaq Global Select Market, which date is within five business days prior to the filing of this Registration Statement.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---